Medigus Announces Presentation on The MUSE™ System During American College of Gastroenterology Annual Scientific Meeting
OMER, Israel, October 19, 2015 – Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Dr. Ali Lankarani, Board member of the Advanced Therapeutic Endoscopy Center (ATEC) at the Borland-Groover Clinic in Jacksonville, FL, will be presenting on the MUSE™ system during the American College of Gastroenterology’s Annual Scientific Meeting and Postgraduate Course, being held October 16- 21, 2015 in Honolulu. The poster, Endoscopic Antireflux Therapies: Are We Near Closing the Treatment Gap in GERD, will be presented on Tuesday October 20th, from 11:00 AM to 12:00 PM (P1648).
“GERD is a common disorder with widespread symptoms that impact millions of Americans each year,” said Dr. Lankarani. “Until the availability of MUSE, there has been a lack of minimally-invasive procedures to provide long-term relief from troublesome reflux symptoms, such as heartburn, chest pains, asthma or coughing, which are not controlled through the use of Proton Pump Inhibitors.”
The MUSE system is an innovative endoscopic device that allows a single physician to perform fundoplasty for the treatment of GERD. According to earlier study results, after five years following treatment with MUSE, more than 90% of participants maintained their normalized quality of life measures and approximately 77% had stopped taking daily medications for treatment of their GERD.
Proton Pump Inhibitors (PPIs) are acid-reducing medications that may provide symptom relief but do not address the root cause of GERD. Alternatively, fundoplasty is the surgical procedure intended to treat GERD at its source by attaching the lower esophageal sphincter to the upper part of the stomach (fundus). Fundoplasty has traditionally been performed surgically or laparoscopically, leaving a treatment gap between drug therapy and invasive surgery for the treatment of GERD.
“In my experience, MUSE can help address the unmet need between drug therapy and invasive surgeries for long-term GERD relief and has the potential to play a key role in closing the treatment gap for GERD patients by offering physicians a technically easy and safe platform to perform fundoplasty,” added Dr. Lankarani.
The MUSE™ System Poster Presentation at ACG
Poster Session # P1648 – “Endoscopic Antireflux Therapies: Are we Near Closing the Treatment Gap in GERD”, Lankarani, Ali; Nieto, José
Tuesday, October 20, 2015 in Exhibit Halls I and II
• 9:30 AM - 3:00 PM – Posters can be viewed
• 11:00 AM – 12:00 PM – Authors will present